Published in Healthcare Mergers, Acquisitions and Ventures Week, April 16th, 2005
According to recent research published in the journal Blood, "In Philadelphia-positive (Ph) leukemia, point mutations within the Bcr-Abl kinase domain emerged as a major mechanism of resistance to imatinib mesylate. We established a cell-based screening strategy for detection of clinically relevant point mutations using Bcr-Abl-transformed Ba/F3 cells. We identified 32 different single-point mutations within the kinase domain of Bcr-Abl."
"The pattern and frequency of mutations in this cell culture-based screen resembled the pattern and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions and Ventures Week